Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.
TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.
Tempus AI: Buy The Post-Earnings Dip
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention reached 126%, signaling strong customer value and recurring demand. Adjusted EBITDA turned positive in Q4, and 2026 guidance projects $65M adjusted EBITDA, though revenue growth is expected to slow to 25%.
Tempus AI, Inc. (TEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Tempus AI, Inc. ever had a stock split?
Tempus AI, Inc. Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Eric Lefkofsky CEO | NASDAQ (NGS) Exchange | 88023B103 CUSIP |
| US Country | 2,400 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tempus AI, Inc. stands as a vanguard healthcare technology company, specializing in delivering cutting-edge diagnostic solutions. Established in 2015 and based in Chicago, Illinois, its operations encompass a comprehensive range of molecular and anatomic pathology tests. Initially known as Tempus Labs, Inc., the company underwent a rebranding to Tempus AI, Inc. in January 2023. Its offerings are designed to support healthcare providers, pharmaceutical entities, biotechnology firms, researchers, and other third-party organizations. Its mission revolves around the fusion of clinical data and artificial intelligence to forge advancements in healthcare outcomes.
Products and Services
Tempus AI, Inc. has curated a diverse portfolio of products and services, each tailored to address various aspects of healthcare diagnostics and research:
- Next Generation Sequencing Diagnostics: Leveraging comprehensive genomic profiling to aid in the identification of DNA mutations responsible for cancers, guiding personalized treatment plans.
- Polymerase Chain Reaction (PCR) Profiling: Enabling rapid detection and identification of genetic material from a specific organism, useful in diagnosing infectious diseases, among others.
- Molecular Genotyping: Provides essential data for understanding genetic predispositions to diseases, facilitating preventive healthcare strategies.
- Insights: Offers a vast library of de-identified clinical, molecular, and imaging data, coupled with a suite of analytical services. It provides pharmaceutical and biotechnology companies with valuable data analytics capabilities, by employing advanced analytical and cloud-compute technologies.
- Trials: A service designed to match clinical trials with suitable candidates, thus accelerating the drug development process for pharmaceutical companies.
- Next; Algos: This suite presents algorithmic tests specifically in the field of oncology, enhancing the speed and accuracy of cancer diagnosis and treatment planning.
- Hub: A comprehensive platform for healthcare providers, facilitating easy ordering, management, and receipt of tests and patient results through both desktop and mobile interfaces.
- Lens: Exclusively for researchers and scientists, this platform allows the exploration, access, and analysis of Tempus's rich data sets, fostering innovation in medical research.
